A toxic antibody is the latest weapon that has proven promising as a broadband treatment for various forms of advanced cancers.
Known as the "Trojan Horse" approach, the chemotherapy drug has proven to be worthy of being replicated from clinical trials to a larger number of patients. It is not a fabulous panacea, but this approach could be as close as we will come.
Researchers from the Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust tested the new treatment in a clinical trial of 147 patients to evaluate their potential benefits and risks of adverse events.
Tisotumab Vedotin or, in short, TV, in short, the drug consists of a monoclonal antibody and a cytotoxic component that can cause fatal damage to cells.
The antibody, if you like, is the spectacular gift horse in front of your opponent's door. Signal flags in membranes, which are called tissue factors, and calls for entry.
While all types of healthy cells have this factor, a variety of tumors use it to get out of control, making it an attractive target for cytotoxic addiction. and destroy chemical weapon.
In this case, monomethyl-Auristatin E, a molecule that prevents the propagation of cells.
The component responsible for this murderous work is what is so exciting about this treatment. Its mechanism of action is completely new ̵
"Our early study shows that it has the potential to treat a large number of different cancers, especially some of those with very low survival rates."
Cervix, bladder, ovaries, endometrium, esophagus, and lungs.
Those who had bladder cancer showed the most impressive response, and at the other end of endometrial carcinoma, 7 percent of respondents were more modest.
"It's exciting see the potential of television in a number of difficult-to-treat cancers, "says the head of the institute e of Cancer Research Executive, Paul Workman.
"I am looking forward to the progress of the clinic, and I hope it will benefit patients who currently have no treatment options."
These advances are slow. Phase I clinical trials began in 2013 with TV safety screening in just 27 patients.
One and a half years later, serious health concerns arose, including signs of severe type 2 diabetes, mucosal inflammation, and fever.
At lower doses, these side effects increased more, though the treatment decreased Still far from problems, with nosebleeds, nausea and fatigue associated with frequent ailments.
However, when it comes to life or death, non-fatal complaints like these can seem trivial in comparison. Phase I tests made room for Phase II, which showed that television would make a big difference to many cancer patients, who would otherwise be ill-treated.
"TV has manageable side effects, and we've seen some good responses from our patients. All had advanced cancer, which had previously been heavily treated with other drugs and had other options," says de Bono.
The next step is to extend the phase II cancer testing to bowel and pancreas while being tested as a second cervical cancer drug that has not gone down after the initial treatments.
It is important to know that this is not a panacea or the end of cancer as we know it. However, if so many promising treatments fail to get past the starting line, it's exciting to see promising cancers that can make a difference.
If all goes well, we could expect a third trial period in a few years comparing the efficacy and safety of the drug with similar treatments.
All this takes time and money, so we can not wait for the TV to become available for some time (if at all). But the proven success of a centuries-old military strategy used in a cancer drug is a good sign of treatments of this nature.
"We urgently need innovative treatments like these that can attack cancer in a whole new way and even stay effective Tumors that have become resistant to standard therapies, "says Workman.
This research was published in The Lancet Oncology .